Sign In
Buy ZTS
$77.59
+1.20 (+1.57%)
At Close: Jun 03, 2026
SDZNY vs. ZTS: Which Stock Should Value Investors Buy Now?
12:41pm, Monday, 18'th Nov 2024
Investors with an interest in Medical - Drugs stocks have likely encountered both Sandoz Group AG Sponsored ADR (SDZNY) and Zoetis (ZTS). But which of these two stocks offers value investors a better
Zoetis: This Beautifully Boring, Slow-Growing Compounder Is A Buy
04:16am, Monday, 18'th Nov 2024
Zoetis, a leading animal health company, has shown impressive growth with a 17.55% CAGR since its IPO, outperforming the S&P 500. The company benefits from increasing global pet ownership and spending
Zoetis: The Major Player in the $500B Pet Market You May Not Have Heard Of
01:00pm, Tuesday, 12'th Nov 2024
The pet industry is growing fast and could reach a global market size of half a trillion dollars by 2032. This episode looks at why people bought more pets during COVID, the trend of treating pets lik
1 Magnificent S&P 500 Dividend Stock Down 12% to Buy After Its Recent Pullback
09:45am, Monday, 11'th Nov 2024
Zoetis looks like a classic example of a premium business trading at a fair price following its recent dip.
Zoetis Appoints Jamie Brannan to Newly Created Chief Commercial Officer Role
09:20am, Monday, 11'th Nov 2024
PARSIPPANY, N. J.--(BUSINESS WIRE)--ZOETIS APPOINTS JAMIE BRANNAN TO NEWLY CREATED CHIEF COMMERCIAL OFFICER ROLE.
Zoetis Q3: Strong Osteoarthritis Pain Franchise
11:18pm, Sunday, 10'th Nov 2024
I reiterate a 'Buy' rating for Zoetis with a one-year target price of $210 per share, driven by strong product performance and strategic divestitures. The Company's osteoarthritis drugs, LIBRELA and S
Zoetis to Participate in Jefferies London Healthcare Conference
08:30am, Thursday, 07'th Nov 2024
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will participate in the Jefferies London Healthcare Conference on Wednesday, November 20, 2024. Wetteny Joseph, Executi
Zoetis Q3 Earnings & Revenues Beat, '24 Outlook Raised, Stock Up
01:10pm, Monday, 04'th Nov 2024
ZTS stock gains as third-quarter results beat both earnings and revenue estimates, driven by strong product sales. Management raises the 2024 outlook.
Zoetis Inc. (ZTS) Q3 2024 Earnings Call Transcript
12:15pm, Monday, 04'th Nov 2024
Zoetis Inc. (NYSE:ZTS ) Q3 2024 Earnings Conference Call November 4, 2024 8:30 AM ET Company Participants Steve Frank - VP of IR Kristin Peck - CEO Wetteny Joseph - CFO Conference Call Participants Er
Zoetis raises full-year guidance on strong Q3 results
11:12am, Monday, 04'th Nov 2024
Zoetis Inc (NYSE:ZTS, ETR:ZOE) delivered another impressive quarter, with revenue and earnings exceeding Wall Street estimates for the third quarter of fiscal year 2024. For the period ended September
Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Zoetis Inc. For Fraud
11:00am, Monday, 04'th Nov 2024
LOS ANGELES, CA / ACCESSWIRE / November 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("
Compared to Estimates, Zoetis (ZTS) Q3 Earnings: A Look at Key Metrics
10:35am, Monday, 04'th Nov 2024
Although the revenue and EPS for Zoetis (ZTS) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Stree
Zoetis raises annual forecasts on strong demand for pet treatments
09:11am, Monday, 04'th Nov 2024
Zoetis raised its annual profit and revenue forecasts on Monday on strong demand for its medicines and vaccines for animals.
Zoetis (ZTS) Q3 Earnings and Revenues Beat Estimates
09:10am, Monday, 04'th Nov 2024
Zoetis (ZTS) came out with quarterly earnings of $1.58 per share, beating the Zacks Consensus Estimate of $1.46 per share. This compares to earnings of $1.36 per share a year ago.
Zoetis Announces Third Quarter 2024 Results
07:00am, Monday, 04'th Nov 2024
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today reported its financial results for the third quarter of 2024 and raised its full year 2024 guidance for revenue a
